K562

K562 is a human cell line derived from a 56-year-old male with chronic myeloid leukemia. It was established in 1972 by the National Institutes of Health (NIH) and has since become one of the most widely used cell lines in biomedical research. The K562 cell line is notable for its ability to differentiate into erythroid cells, making it a valuable model for studying erythropoiesis, the process of red blood cell production.

K562 cells are often used in research to study various aspects of cell biology, including gene expression, protein synthesis, and cellular signaling pathways. They are also commonly used in the development and testing of new drugs and therapies, particularly those targeting hematopoietic diseases. The cell line's ability to differentiate into erythroid cells makes it particularly useful for studying erythropoiesis and related disorders.

In addition to its use in basic research, K562 cells have been used in clinical trials and translational research. For example, they have been used to study the effects of certain drugs on erythropoiesis and to develop new therapies for anemia and other hematopoietic disorders. The cell line's well-characterized genetic and phenotypic properties have made it a valuable tool for researchers in the field of hematology.

K562 cells are also used in educational settings to teach students about cell biology, genetics, and other related topics. Their ease of cultivation and well-documented characteristics make them an ideal model system for teaching purposes. Overall, the K562 cell line has played a significant role in advancing our understanding of erythropoiesis and has contributed to the development of new therapies for hematopoietic diseases.